Navigation Links
Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinson's Therapeutic Targets
Date:7/14/2009

NEW YORK, July 14 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced approximately $2.1 million in total funding to 10 research teams working to validate therapeutic targets for Parkinson's disease.

Target validation is an essential and historically underresourced phase of drug development in which researchers work to determine whether a molecule or mechanism of interest is a true drug target. While researchers have continued to identify novel targets in recent years through genetic, biochemical and epidemiological studies, a lack of funding for validation studies has long been a major roadblock to the efficient translation of these discoveries into practical therapies that benefit people living with PD.

The Foundation's Target Validation initiative, one of MJFF's Edmond J. Safra Core Programs for PD Research, provides intellectual and financial resources to help push potential PD drug targets one step closer to clinical trials and Parkinson's patients.

Funded projects are listed below. Detailed information, including grant abstracts and researcher bios, is available on the Foundation's Searchable Database of Funded Grants.

As with all MJFF grants, full funding is dependent on the achievement of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.

The transcription factor Nrf2 as a target to reduce neurodegeneration and neuroinflammation in Parkinson's disease

Antonio Cuadrado, PhD, Universidad Autonoma de Madrid, Spain

Neuroprotection by PXDNL, a novel heme-containing peroxidase

J. Timothy Greenamyre, MD, PhD, University of Pittsburgh

Validation of Nox1/Rac1, a novel molecular source of reactive oxygen species in the nigrostriatal pathway, as a target for Parkinson's disease therapy

Yoon-Seong Kim, MD, PhD, Weill Medical College of Cornell University

Upregulation of MsrA: A neuroprotective strategy for the treatment of Parkinson's disease

Deniz Kirik, MD, PhD, Lund University (Sweden) and Jean-Christophe Rochet, PhD, Purdue University

Use of Smo1 antagonists to boost endogenous GDNF expression in the adult striatum

Andreas H. Kottman, PhD, Columbia University

Polo-like kinases as therapeutic targets for Parkinson's disease

Hilal A. Lashuel, PhD, and Patrick Aebischer, MD, Ecole Polytechnique Federale de Lausanne (Switzerland) and Deniz Kirik, MD, PhD, Lund University (Sweden)

Validation of cyclophilin D, a protein involved in the mitochondrial permeability transition, as a target for Parkinson's disease therapy

Mathieu Lesort, PhD, University of Alabama at Birmingham

The therapeutic role of CMA-MEF2D in the survival of dopamine neurons

Zixu Mao, PhD, Emory University

SHP-2 phosphatase: A new pharmacological target for Parkinson's disease?

Maria-Cristina Missale, PhD, University of Brescia (Italy)

Validation of Nurr1 as a Drug Target for the Treatment of PD

Demetrios K. Vassilatis, PhD, Foundation for Biomedical Research of the Academy of Athens, Greece

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the coming decade through an aggressively funded research agenda. The Foundation has funded over $145 million in research to date.


'/>"/>
SOURCE The Michael J. Fox Foundation for Parkinson's Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):